XML 49 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Cullinan-MICA Asset Acquisition - Additional Information (Details)
1 Months Ended 9 Months Ended
May 28, 2020
USD ($)
shares
Jun. 30, 2021
USD ($)
shares
May 31, 2020
shares
Sep. 30, 2021
USD ($)
Milestone
shares
Sep. 30, 2020
USD ($)
Dec. 31, 2020
shares
Schedule Of Asset Acquisition [Line Items]            
Common stock, shares authorized       150,000,000   34,900,878
Common stock, shares outstanding       43,660,909   29,831,125
Voting agreement description       Voting Agreement dated May 28, 2020, among the Company and other stockholders of MICA, MICA increased the size of its board of directors from four to five directors, of which three directors are designated by the Company.    
Acquired in-process research and development assets | $         $ 6,447,000  
PDI Therapeutics, Inc.            
Schedule Of Asset Acquisition [Line Items]            
Number of share authorized for issuance 72,890,797          
Common stock, shares authorized 39,000,000          
Preferred stock shares authorized 33,890,797          
MICA            
Schedule Of Asset Acquisition [Line Items]            
Number of shares outstanding     22,829,406      
Common stock, shares outstanding     602,784      
MICA Equity Plan            
Schedule Of Asset Acquisition [Line Items]            
Common stock, shares reserved     2,034,457      
MICAs Directors and Officers, as well as Former Employees of PDI Therapeutics | MICA Equity Plan            
Schedule Of Asset Acquisition [Line Items]            
Common stock, shares reserved     1,826,402      
Series A Senior Preferred Stock            
Schedule Of Asset Acquisition [Line Items]            
Number of share purchased as part of asset acquisition     5,385,787      
Series A Senior Preferred Stock | PDI Therapeutics, Inc.            
Schedule Of Asset Acquisition [Line Items]            
Preferred stock shares authorized 19,786,914          
Series A Senior Preferred Stock | MICA            
Schedule Of Asset Acquisition [Line Items]            
Ownership percentage in outstanding shares       88.50%    
Series A Senior Preferred Stock | MICA Board Authorized First Additional Closing            
Schedule Of Asset Acquisition [Line Items]            
Number of share purchased as part of asset acquisition   5,385,787        
Share purchased price as part of asset acquisition | $   $ 7,100,000        
Ownership percentage increased in outstanding shares   45.00%        
Series A Senior Preferred Stock | Certain Existing Shareholders | MICA Board Authorized First Additional Closing            
Schedule Of Asset Acquisition [Line Items]            
Number of share purchased as part of asset acquisition   702,495        
Share purchased price as part of asset acquisition | $   $ 900,000        
Series A Junior Preferred Stock | PDI Therapeutics, Inc.            
Schedule Of Asset Acquisition [Line Items]            
Preferred stock shares authorized 1,999,998          
Series A Junior Preferred Stock | MICA            
Schedule Of Asset Acquisition [Line Items]            
Preferred stock shares outstanding     6,088,282      
Series A Junior Preferred Stock | Cullinan Oncology, LLC            
Schedule Of Asset Acquisition [Line Items]            
Preferred stock shares outstanding     5,385,787      
Series A-1 Junior Preferred Stock | PDI Therapeutics, Inc.            
Schedule Of Asset Acquisition [Line Items]            
Preferred stock shares authorized 652,371          
Series A-2 Junior Preferred Stock | PDI Therapeutics, Inc.            
Schedule Of Asset Acquisition [Line Items]            
Preferred stock shares authorized 11,451,514          
Series A, A-1 and A2 Junior Preferred Stock | MICA            
Schedule Of Asset Acquisition [Line Items]            
Preferred stock shares outstanding     14,103,883      
Fully Diluted Shares | MICA            
Schedule Of Asset Acquisition [Line Items]            
Ownership percentage in outstanding shares       24.00%    
Ownership percentage can increase with subsequent closings       54.00%    
Research and Development Expense            
Schedule Of Asset Acquisition [Line Items]            
Acquired in-process research and development assets | $         $ 6,400,000  
Series A Senior Preferred Stock Purchase Agreement            
Schedule Of Asset Acquisition [Line Items]            
Number of additional closings | Milestone       2    
Series A Senior Preferred Stock Purchase Agreement | Series A Senior Preferred Stock | PDI Therapeutics, Inc.            
Schedule Of Asset Acquisition [Line Items]            
Number of share purchased as part of asset acquisition 5,385,787          
Share purchased price as part of asset acquisition | $ $ 7,100,000          
Series A Senior Preferred Stock Purchase Agreement | Series A Senior Preferred Stock | PDI Therapeutics, Inc. | Certain Existing PDI Therapeutics Shareholders            
Schedule Of Asset Acquisition [Line Items]            
Number of share purchased as part of asset acquisition 702,495          
Share purchased price as part of asset acquisition | $ $ 900,000          
Series A Senior Preferred Stock Purchase Agreement | Maximum            
Schedule Of Asset Acquisition [Line Items]            
Proceeds from preferred stock | $       $ 26,000,000.0